What is Sermorelin?
Sermorelin is GHRH(1-29)-NH2, the biologically active N-terminal fragment of growth-hormone-releasing hormone. It has a long history in endocrine research and historical clinical use.
Proposed mechanism
Sermorelin stimulates pituitary somatotrophs through the GHRH receptor, producing endogenous growth-hormone release rather than acting as growth hormone itself.
What has been published?
Controlled human pharmacology studies in healthy adults showed that GHRH(1-29)-NH2 stimulates GH release and characterized its dose-response and pharmacokinetics.
Current human evidence
Human evidence clearly supports acute GH stimulation. That does not establish modern consumer claims around anti-ageing, physique enhancement, recovery or longevity.
Regulatory status
Sermorelin should not be presented as a currently FDA-approved anti-ageing or performance treatment. Regulatory and availability history is distinct from evidence that it stimulates GH.
Possible areas of research interest
- Pituitary physiology
- Growth-hormone stimulation
- GHRH pharmacology
- Endocrine testing history
Important limitations
- GH stimulation does not prove broad clinical benefits
- Much of the foundational literature is older
- Long-term healthy-user outcomes are not established
- Claims should be separated from historical diagnostic/clinical use
References
AEVLI prioritizes primary publications and regulator materials over anecdotal claims.